SCHEMBL4468273

SCHEMBL4468273

Cc1cc(=O)c(-c2ccc(-c3ccc4c(c3)OCO4)nc2)c(C)o1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.45
KDM4E B2RXH2 6/20 0.45
POLB P06746 3/20 0.45
SMN1; SMN2 Q16637 6/20 0.42
HSD17B10 Q99714 3/20 0.42
MAPT P10636 7/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
FYN P06241 2/20 0.41
NPC1 O15118 7/20 0.40
RAB9A P51151 6/20 0.40
LMNA P02545 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX5 P09917 1/20 0.40
ADORA3 P0DMS8 2/20 0.39
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4480243 0.80 BRD4 (0.47) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL13754677 0.80 PTGS2 (0.44) ALDH1A1HSD17B10MAPTUSP2CYP3A4
SCHEMBL4485765 0.79 MAPT (0.37) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL4485980 0.77 BRD4 (0.40) ALDH1A1KDM4EPOLBSMN1; SMN2MAPT
SCHEMBL13761581 0.76 PTGS2 (0.48) KDM4EMAPTIDO1TDO2CYP1A2
SCHEMBL3397603 0.76 KDM1A (0.40) ALDH1A1KDM4ESMN1; SMN2FYNNPC1
SCHEMBL4478340 0.76 NOTUM (0.35)
SCHEMBL15759173 0.75 ALDH1A1 (0.57) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10
SCHEMBL4471452 0.74 KDM1A (0.44) ALDH1A1KDM4EHSD17B10NPC1RAB9A
SCHEMBL13754690 0.74 BRD4 (0.45) ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP ALDH1A1 287/4885KDM4E 1311/4885POLB 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.